Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART.

TitlePredictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART.
Publication TypeJournal Article
Year of Publication2014
AuthorsHarezlak, J, Cohen, R, Gongvatana, A, Taylor, M, Buchthal, S, Schifitto, G, Zhong, J, Daar, ES, Alger, JR, Brown, M, Singer, EJ, Campbell, TB, McMahon, D, So, YT, Yiannoutsos, CT, Navia, BA
Corporate AuthorsHIV Neuroimaging Consortium,
JournalJ Neurovirol
Volume20
Issue3
Pagination294-303
Date Published2014 Jun
ISSN1538-2443
KeywordsAdult, AIDS Dementia Complex, Anti-Retroviral Agents, Aspartic Acid, Basal Ganglia, Choline, Chronic Disease, Creatine, External, Female, Frontal Lobe, Gray Matter, Humans, Longitudinal Studies, Magnetic Resonance Spectroscopy, Male, Middle Aged, Predictive Value of Tests, Protons, White Matter
Abstract

The reasons for persistent brain dysfunction in chronically HIV-infected persons on stable combined antiretroviral therapies (CART) remain unclear. Host and viral factors along with their interactions were examined in 260 HIV-infected subjects who underwent magnetic resonance spectroscopy (MRS). Metabolite concentrations (NAA/Cr, Cho/Cr, MI/Cr, and Glx/Cr) were measured in the basal ganglia, the frontal white matter, and gray matter, and the best predictive models were selected using a bootstrap-enhanced Akaike information criterion (AIC). Depending on the metabolite and brain region, age, race, HIV RNA concentration, ADC stage, duration of HIV infection, nadir CD4, and/or their interactions were predictive of metabolite concentrations, particularly the basal ganglia NAA/Cr and the mid-frontal NAA/Cr and Glx/Cr, whereas current CD4 and the CPE index rarely or did not predict these changes. These results show for the first time that host and viral factors related to both current and past HIV status contribute to persisting cerebral metabolite abnormalities and provide a framework for further understanding neurological injury in the setting of chronic and stable disease.

DOI10.1007/s13365-014-0246-6
Alternate JournalJ Neurovirol
PubMed ID24696364
PubMed Central IDPMC4041596
Grant ListU01MH083500 / MH / NIMH NIH HHS / United States
U24 MH100929 / MH / NIMH NIH HHS / United States
R01 NS036524 / NS / NINDS NIH HHS / United States
U01 MH083500 / MH / NIMH NIH HHS / United States
UM1 AI069424 / AI / NIAID NIH HHS / United States
UL1 RR025780 / RR / NCRR NIH HHS / United States
U24 MH100928 / MH / NIMH NIH HHS / United States
NS038841 / NS / NINDS NIH HHS / United States
R24 NS038841 / NS / NINDS NIH HHS / United States
UL1 TR001108 / TR / NCATS NIH HHS / United States
P30 AG028740 / AG / NIA NIH HHS / United States
U54 EB020403 / EB / NIBIB NIH HHS / United States
R01 MH099921 / MH / NIMH NIH HHS / United States
AI069424 / AI / NIAID NIH HHS / United States
R00 AA020235 / AA / NIAAA NIH HHS / United States
U01MH083506 / MH / NIMH NIH HHS / United States
NS36524 / NS / NINDS NIH HHS / United States
U01 MH083506 / MH / NIMH NIH HHS / United States
UL1 TR001082 / TR / NCATS NIH HHS / United States
U01 AI069424 / AI / NIAID NIH HHS / United States
RR025780 / RR / NCRR NIH HHS / United States
MH083506 / MH / NIMH NIH HHS / United States